Add 2 More Reports For 20% off

Report Overview

Tuberculosis is a bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs. According to the World Health Organisation, around 10.8 million people suffered from tuberculosis in 2023, including 6 million men, 3.6 million women, and 1.3 million children. Tuberculosis is curable and preventable. However, multidrug-resistant tuberculosis poses a significant health challenge, with only 2 in 5 drug-resistant tuberculosis patients able to access treatments in 2023. Thus, the emergence of multidrug-resistant tuberculosis strains is accelerating the development of new drugs that are effective against resistant forms.

  • Major companies involved in the tuberculosis pipeline drugs market include GlaxoSmithKline and Serum Institute of India Pvt. Ltd., among others.
  • Leading drugs currently under the pipeline include Sudapyridine (WX-081) and VPM1002, among others.
  • The rising incidence of drug-resistant tuberculosis and the growing public-private partnerships between research institutions and pharmaceutical companies are anticipated to accelerate the availability of new treatments.

Report Coverage

The Tuberculosis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into tuberculosis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for tuberculosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The tuberculosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from tuberculosis.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to tuberculosis.

Tuberculosis Drug Pipeline Outlook

Tuberculosis (TB) is a multisystemic disease that usually attacks the lungs but can spread to other parts of the body. It is estimated that a quarter of the global population has been infected with the tuberculosis bacteria. Studies show that nearly 5 to 10% of individuals infected with tuberculosis tend to develop symptoms and TB disease. Certain factors such as a weakened immune system, tobacco use, and diabetes, among others, can increase a person’s risk for tuberculosis.

Treatment for tuberculosis includes a combination of antibiotics, with the treatment duration typically lasting for four, six, or nine months. Isoniazid, rifampin, moxifloxacin, pyrazinamide, ethambutol, and rifapentine are some of the popular antibiotics that are prescribed to patients. Advancements in biotechnology and pharmacology such as high-throughput screening and computational modeling are expected to expedite the development of new drugs. Moreover, the rising investment in tuberculosis research and treatment programs are anticipated to fuel the drug pipeline expansion in the coming years.

Tuberculosis – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of tuberculosis drugs based on several segmentations including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Monoclonal Antibody
  • Small Molecule
  • Peptide

By Route of Administration

  • Oral
  • Parenteral
  • Others

Tuberculosis – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for tuberculosis. Currently, there are around 55 drugs undergoing Phase II clinical development.

Tuberculosis – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the tuberculosis pipeline analysis include monoclonal antibody, small molecule, and peptide. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for tuberculosis.

Tuberculosis Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the tuberculosis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in tuberculosis clinical trials:

  • GlaxoSmithKline
  • Serum Institute of India Pvt. Ltd.
  • Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
  • BioNTech SE
  • Archivel Farma S.L.
  • Janssen Research & Development, LLC
  • Shanghai Jiatan Pharmatech Co., Ltd.

Tuberculosis – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: Sudapyridine, Drug: Bedaquiline

Sponsored by Shanghai Jiatan Pharmatech Co., Ltd, the objective of this Phase III, multicenter, double-blind, active-controlled Phase III study is to examine the efficacy and safety of the drug candidate Sudapyridine (WX-081) in combination with a background regimen for the treatment of rifampicin-resistant pulmonary tuberculosis. The study is expected to be completed by October 2026 and has around 450 participants.

Biological: VPM1002, Biological: BCG SII

Serum Institute of India Pvt. Ltd. is conducting a Phase III clinical trial aimed at investigating the safety ...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Reasons To Buy This Report

The Tuberculosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for tuberculosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within tuberculosis pipeline insights.

Key Questions Answered in the Tuberculosis – Pipeline Insight Report

  • What is the current landscape of tuberculosis pipeline drugs?
  • How many companies are developing tuberculosis drugs?
  • How many phase III and phase IV drugs are currently present in tuberculosis pipeline drugs?
  • Which companies/institutions are leading the tuberculosis drug development?
  • What is the efficacy and safety profile of tuberculosis pipeline drugs?
  • What are the opportunities and challenges present in the tuberculosis drug pipeline landscape?
  • Which company is conducting major trials for tuberculosis drugs?
  • What geographies are covered for tuberculosis clinical trials?
  • What are emerging trends in tuberculosis clinical trials?

Related Reports

Global Tuberculosis Treatment Market

Anti Tuberculosis Therapeutics Market

Global Clinical Trials Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Drug Pipeline by Clinical Trial Phase

  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

Route of Administration

  • Oral
  • Parenteral
  • Others

Drug Classes

  • Monoclonal Antibody
  • Small Molecule
  • Peptide

Leading Sponsors Covered

  • GlaxoSmithKline
  • Serum Institute of India Pvt. Ltd.
  • Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
  • BioNTech SE
  • Archivel Farma S.L.
  • Janssen Research & Development, LLC
  • Shanghai Jiatan Pharmatech Co., Ltd.

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Others

Purchase Full Report

Datasheet

 

USD 1,999

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 2,499

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 3,499

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 4,499

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124